Reaction mass of 2-aminoethanol and 6-[(p-tosyl)amino]hexanoic acid, compound with 2-aminoethanol (1:1)

Endpoint summary

Description of key information

The toxicity of the carboxylic acid component of the registered substance following a repeated exposure was determined in accordance with the OECD Guideline for Testing of Chemicals 422. The NOEL and NOAEL for the test substance is defined as 400 mg/kg bw/day. The LOEL for the test substance is defined as 1600 mg/kg bw/day. 

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Reference

Endpoint:

short-term repeated dose toxicity: oral

Remarks:

combined repeated dose and reproduction / developmental screening

Type of information:

migrated information: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Study period:

From 23 May 2012 to 30 September 2013

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Study was conducted by a GLP accredited laboratory using OECD Testing Guideline 422. The study was conducted on 6-[(p-Tosyl)amino]hexanoic acid, which is the carboxylic acid component of the registered substance.

Reason / purpose for cross-reference:

reference to same study

Reason / purpose for cross-reference:

reference to other study

Qualifier:

according to guideline

Guideline:

OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)

Deviations:

no

Principles of method if other than guideline:

Daily administration by stomach tube for 54 days

GLP compliance:

yes

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

male

Details on test animals or test system and environmental conditions:

TEST ANIMALS- Source: Charles River, Germany, D-97633 Sulzfeld- Age at purchase: 11 weeks - weight rage at time of grouping: males, 175-200 g- Fasting period before study: no- Housing: 2 per cage, - Cages: TECHNIPLAST filter top cages type 2145 F with an G-Temp (PSU) durable filter cover, 480x265x210 mm³, floor area 940 cm²,- Source: Techniplast Company, Italy- Diet: ad libitum, M3, BONAGRO Ltd., reg. CZ 10174, Czech Republic- Water: ad libitum, tap water- Acclimation period: 9 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 22 +/- 2- Humidity (%): 40 - 70- Photoperiod (hrs dark / hrs light): 12/12

Route of administration:

oral: gavage

Vehicle:

water

Details on oral exposure:

VEHICLE: Suspension in water- Amount of vehicle: 10 ml/kg- single daily administration at similar times each day

Analytical verification of doses or concentrations:

no

Duration of treatment / exposure:

54 administrations, (2 weeks before mating, 2 weeks during mating and 26 days after mating)dissection ca. 24 hours after the last administration

Frequency of treatment:

daily

Remarks:

Doses / Concentrations:0, 100, 400, 1600 mg/kg body weight (mg/kg bw)Basis:actual ingested

No. of animals per sex per dose:

12 males and 12 females per group including control group. 5 males and 5 females per satellite group.

Control animals:

yes

Details on study design:

- Control groups: drinking water- Dose selection rationale: Results of an acute toxicity study with oral administration to male and female rats- Result: no effects up to and including 2000 mg/kg bw.- Rationale for animal assignment: randomly grouped- Section schedule rationale: all animals were sacrificed

Positive control:

no

Observations and examinations performed and frequency:

CAGE SIDE OBSERVATIONS: Yes - Time schedule: dailyBODY WEIGHT: Yes - Time schedule for examinations: on administration days 1, 8, 15, 22, 29, 36, 42, 50 and on day of autopsyFOOD CONSUMPTION : 2 weeks before mating, after 2 week mating period and weekly until the end of the studyHAEMATOLOGY: Yes - Time schedule for collection of blood: day 14 (before mating) and prior to autopsy from the satellite groups and from the control and highest dose group.CLINICAL CHEMISTRY: Yes- Time schedule for collection of blood:day 14 (before mating) and prior to autopsy from the satellite groups and from the control and high dose group.URINALYSIS: No

Sacrifice and pathology:

GROSS PATHOLOGY: Yes- Organ weights: brain, heart, thymus, spleen, liver, testis, epididymis, kidney, adrenal glandHISTOPATHOLOGY: Yes: high dose and control animals- Organ: medulla oblongata, brain, heart, pancreas + lymph node, spleen, liver, lung, small intestine, stomach, kidneys, adrenal gland, testes, prostrate, urinary bladder, bone + bone marrow, thymus, trachea, white + brown fat, muscle, pituitary gland

Statistics:

Statistical evaluation was operated using the software SPPS version 16.0. Group data were represented by mean, standard deviation and median. Statistical analysis in case of data measured once during the study (organ weight, haematology, clinical chemistry) : Mann-Whitney U test for pairwise comparison between control and individual experimental groups on significance level alpha = 0.05.Statistical analysis in case of repeated data measurement (body weight, food intake): Repeated measures ANOVA (procedure General Linear Model (GLM) for Repeated Measures in SPSS statistical software).

Clinical signs:

no effects observed

Mortality:

no mortality observed

Body weight and weight changes:

effects observed, treatment-related

Description (incidence and severity):

statistically significant decrease after dosages of 1600 mg/kg bw./day

Food consumption and compound intake (if feeding study):

no effects observed

Food efficiency:

not examined

Water consumption and compound intake (if drinking water study):

not examined

Ophthalmological findings:

not examined

Haematological findings:

no effects observed

Clinical biochemistry findings:

no effects observed

Urinalysis findings:

not examined

Behaviour (functional findings):

not examined

Organ weight findings including organ / body weight ratios:

no effects observed

Gross pathological findings:

no effects observed

Histopathological findings: non-neoplastic:

no effects observed

Histopathological findings: neoplastic:

no effects observed

Details on results:

CLINICAL SIGNS:- 100, 400 and 1600 mg/kg bw/day: no differences to the control animals observableMORTALITY: noBODY WEIGHT GAIN: 1600 mg/kg bw: reduced FOOD CONSUMPTION: no statistical differencesHAEMATOLOGY/ CLINICAL CHEMISTRY:Haematology and clinical chemistry reveals some statistically significant differences, but these were neither related to dosage not confirmed by the findings in other groups, for example by the results of the satellite groups, or the effects are of biological low relevance i.e..URINALYSIS: not examinedNEUROBEHAVIOUR: not examinedORGAN WEIGHTS: no statistical differencesGROSS PATHOLOGY: no dosage related effectsHISTOPATHOLOGY: NON-NEOPLASTIC: no statistical differencesHISTOPATHOLOGY: NEOPLASTIC: no statistical differencesHISTORICAL CONTROL DATA: not given

Dose descriptor:

NOEL

Effect level:

400 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: decrease in body weight (not exceeding 10%)

Dose descriptor:

NOAEL

Effect level:

400 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: decrease in body weight (not exceeding 10%)

Dose descriptor:

LOEL

Effect level:

1 600 mg/kg bw/day (actual dose received)

Based on:

test mat.

Sex:

male

Basis for effect level:

other: decrease in body weight (not exceeding 10%)

Critical effects observed:

not specified

Conclusions:

Daily dosages of 0, 100, 400, and 1600 mg/kg bw of the test substance were administered by stomach tube to groups of 12 male rats for 54 days. Satellite animals in a control and the highest dose group (1600mg/kg bw) with 5 individual each were also included. The test-article was formulated in drinking water and administered in 10 ml/kg bw.At dosages of 100 and 400 mg/kg bw. the animals showed no differences to the control animals (NOAEL).1600 mg ASC plus/kg bw. , considered as the LOEC, may have induced an influence on the body weight gain of the males (and the survival of pups until day 4 after birth).NOAEL: 400 mg/kg bw.

Executive summary:

The repeated dose toxicity of the test substance to rats was determined in accordance with the OECD Guideline for Testing of Chemicals 422. Doses of 0, 100, 400, and 1600 mg/kg bw/day of the test substance were administered by stomach tube to groups of 12 male rats for 54 days. The test-article was formulated in drinking water and administered in 10 ml/kg bw. At dosages of 100 and 400 mg/kg bw/day the animals showed no differences to the control animals (NOEL). All examined organs and tissues showed a normal histological structure. 1600 mg/kg bw/day may have induced an influence on the body weight gain of the males (and the survival of pups until day 4 after birth). The NOEL and NOAEL for the test substance is defined as 400 mg/kg bw/day. The LOEL for the test substance is defined as 1600 mg/kg bw/day.

Read-across between the carboxylic acid (6-[(p-Tosyl)amino]hexanoic acid) and the registered substance is considered justified as the registered substance is manufactured directly from 6-[(p-Tosyl)amino]hexanoic acid by simple neutralisation with 2-aminoethanol in water. In water as they are in the reaction mass, the acid and amine components of the Reaction mass of 2-aminoethanol and 6-[(p-tosyl)amino]hexanoic acid, compound with 2-aminoethanol (1:1) are completely dissociated and behave essentially as independent substances. Toxicity of 2-aminoethanol is local and due to its high pH value. In the reaction mass, it acts as a pH-control for the 6-[(p-Tosyl)amino]hexanoic acid, so no local toxicity is expected. No long-term systemic toxicity is expected as the substance will rapidly metabolise with NH3 and acetyl-CoA as its final degradation products. Therefore, it is considered that the acid component of the reaction mass will have a more significant impact on the outcome of any (eco)toxicological or environmental tests. The pKa of the carboxylic acid group in the reaction mass. As a result, 6-[(p-Tosyl)amino]hexanoic acid will respond to changes of pH in the same way whether it is in the salt form or as the parent carboxylic acid and hence its bioavailability will be the same. As 6-[(p-tosyl)amino]hexanoic acid, the registered substance is not considered to be toxic following a repeated exposure and does not need to be classified as such according to EU CLP criteria.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

NOAEL

400 mg/kg bw/day

Study duration:

subacute

Species:

rat

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

The repeated dose toxicity of the test substance to rats was determined in accordance with the OECD Guideline for Testing of Chemicals 422. Doses of 0, 100, 400, and 1600 mg/kg bw/day of the test substance were administered by stomach tube to groups of 12 male rats for 54 days. The test-article was formulated in drinking water and administered in 10 ml/kg bw. At dosages of 100 and 400 mg/kg bw/day the animals showed no differences to the control animals (NOEL). All examined organs and tissues showed a normal histological structure. 1600 mg/kg bw/day may have induced an influence on the body weight gain of the males (and the survival of pups until day 4 after birth). The NOEL and NOAEL for the test substance is defined as 400 mg/kg bw/day. The LOEL for the test substance is defined as 1600 mg/kg bw/day.

Read-across between the carboxylic acid (6-[(p-Tosyl)amino]hexanoic acid) and the registered substance is considered justified as the registered substance is manufactured directly from 6-[(p-Tosyl)amino]hexanoic acid by simple neutralisation with 2-aminoethanol in water. In water as they are in the reaction mass, the acid and amine components of the Reaction mass of 2-aminoethanol and 6-[(p-tosyl)amino]hexanoic acid, compound with 2-aminoethanol (1:1) are completely dissociated and behave essentially as independent substances. Toxicity of 2-aminoethanol is local and due to its high pH value. In the reaction mass, it acts as a pH-control for the 6-[(p-Tosyl)amino]hexanoic acid, so no local toxicity is expected. No long-term systemic toxicity is expected as the substance will rapidly metabolise with NH3 and acetyl-CoA as its final degradation products. Therefore, it is considered that the acid component of the reaction mass will have a more significant impact on the outcome of any (eco)toxicological or environmental tests. The pKa of the carboxylic acid group in the reaction mass. As a result, 6-[(p-Tosyl)amino]hexanoic acid will respond to changes of pH in the same way whether it is in the salt form or as the parent carboxylic acid and hence its bioavailability will be the same.

As 6-[(p-Tosyl)amino]hexanoic acid is not considered toxic via repeated oral exposure, the registered substance does not need to be classified as such according to EU CLP criteria.

Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
Study was conducted by a GLP accredited laboratory using OECD Testing Guideline 422. The study was conducted on 6-[(p-Tosyl)amino]hexanoic acid, which is the carboxylic acid component of the registered substance. The NOEL and NOAEL for the test substance is defined as 400 mg/kg bw/day. The LOEL for the test substance is defined as 1600 mg/kg bw/day.

Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
In accordance with REACH, Annex XI, no testing is required as no significant inhalation exposure is expected in all scenarios of the manufacture and all identified uses. The substance is only associated with industrial uses and is handled by professional users with protective equipment in controlled conditions. Moreover, the substance will only be used in diluted form.

Justification for selection of repeated dose toxicity inhalation - local effects endpoint:
In accordance with REACH, Annex XI, no testing is required as no significant inhalation exposure is expected in all scenarios of the manufacture and all identified uses. The substance is only associated with industrial uses and is handled by professional users with protective equipment in controlled conditions. Moreover, the substance will only be used in diluted form.

Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
In accordance with REACH, Annex XI, no testing is required as no significant dermal exposure is expected in all scenarios of the manufacture and all identified uses. The substance is only associated with industrial uses and is handled by professional users with protective equipment in controlled conditions. Moreover, the substance will only be used in diluted form.

Justification for selection of repeated dose toxicity dermal - local effects endpoint:
In accordance with REACH, Annex XI, no testing is required as no significant dermal exposure is expected in all scenarios of the manufacture and all identified uses. The substance is only associated with industrial uses and is handled by professional users with protective equipment in controlled conditions. Moreover, the substance will only be used in diluted form.

Justification for classification or non-classification

Read-across between the carboxylic acid (6-[(p-Tosyl)amino]hexanoic acid) and the registered substance is considered justified as the registered substance is manufactured directly from 6-[(p-Tosyl)amino]hexanoic acid by simple neutralisation with 2-aminoethanol in water. In water as they are in the reaction mass, the acid and amine components of the Reaction mass of 2-aminoethanol and 6-[(p-tosyl)amino]hexanoic acid, compound with 2-aminoethanol (1:1) are completely dissociated and behave essentially as independent substances. Toxicity of 2-aminoethanol is local and due to its high pH value. In the reaction mass, it acts as a pH-control for the 6-[(p-Tosyl)amino]hexanoic acid, so no local toxicity is expected. No long-term systemic toxicity is expected as the substance will rapidly metabolise with NH3 and acetyl-CoA as its final degradation products. Therefore, it is considered that the acid component of the reaction mass will have a more significant impact on the outcome of any (eco)toxicological or environmental tests. The pKa of the carboxylic acid group in the reaction mass. As a result, 6-[(p-Tosyl)amino]hexanoic acid will respond to changes of pH in the same way whether it is in the salt form or as the parent carboxylic acid and hence its bioavailability will be the same.

As 6-[(p-Tosyl)amino]hexanoic acid is not considered toxic via repeated oral exposure, the registered substance does not need to be classified as such according to EU CLP criteria.